Two independent CRISPR screens for modulators of BRCA-associated breast tumour sensitivity to PARP inhibitors, an established treatment in BRCA-deficient breast cancer, have shown that genomic inhibition DNPH1 sensitises BRCA-deficient cells to treatment with PARP inhibitors31,32. Here, DNPH1 is linked to breast cancer.